Microbiotica
Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.
£36MSeries C first close
ParticipantCI
Cambridge Innovation Capital
Activity from announced rounds
Activity in this selectionOct 19, 2026 · Jul 22, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $125M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSalience Labs
Salience Labs develops silicon photonic switches for datacenter operators connecting large AI computing clusters.
$125MSeries B
Participant